Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;5(23):476.
doi: 10.21037/atm.2017.10.24.

Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists-what will REWIND add?

Keith C Ferdinand  1 , Indrajeet Mahata  1
Affiliations
Editorial

Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists-what will REWIND add?

Keith C Ferdinand et al. Ann Transl Med. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. KC Ferdinand is a consultant for Amgen, Sanofi, Boehringer-Ingelheim, Quantum Genomics, and Novatis. Dr. I Mahata has no conflicts of interest to declare.

Comment on

References

    1. Tancredi M, Rosengren A, Svensson AM, et al. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med 2015;373:1720-32. 10.1056/NEJMoa1504347 - DOI - PubMed
    1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation 2017;135:e146-e603. 10.1161/CIR.0000000000000485 - DOI - PMC - PubMed
    1. Gerstein HC, Colhoun HM, Dagenais GR, et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab 2017. [Epub ahead of print]. 10.1111/dom.13028 - DOI - PubMed
    1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53. 10.1016/S0140-6736(98)07019-6 - DOI - PubMed
    1. Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 2007;356:2457-71. 10.1056/NEJMoa072761 - DOI - PubMed

LinkOut - more resources